名称：rViMIP-2
Synonyms：Viral Macrophage Inflammatory Protein II, vMIP-1B, MIP-II, vMIP-2
Accession：Q98157
GeneID：4961514
Source：Escherichia coli.
Molecular Weight：Approximately 8.0 kDa, a single, non-glycosylated polypeptide chain containing 70 amino acids.
Quantity：10µg/50µg/1000µg
AA Sequence：LGASWHRPDK CCLGYQKRPL PQVLLSSWYP TSQLCSKPGV IFLTKRGRQV CADKSKDWVK KLMQQLPVTA
Purity：> 97 % by SDS-PAGE and HPLC analyses.
Biological Activity：Fully biologically active when compared to standard. The specific activity is determined by the inhibitory effect on monocyte migration response to human MIP-1 alpha using a concentration range of 1.0µg-10.0µg/ml of viral MIP-2 will inhibit 25ng/ml of human MIP-1 alpha.
Physical Appearance：Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation：Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, pH 7.4, 150mM NaCl.
Endotoxin：Less than 1 EU/μg of rViMIP-2 as determined by LAL method.
Reconstitution：We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Stability & Storage：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reference：1. Liwang AC, Wang ZX, Sun Y, et al. 1999. Protein Sci, 8: 2270-80.
2. Morris KV, Higgins J, Shen X, et al. 2003. Virus Res, 94: 103-12.
3. Luttichau HR. 2008. Virol J, 5: 50.
4. Shao W, Fernandez E, Sachpatzidis A, et al. 2001. Eur J Biochem, 268: 2948-59.
Background：Viral MIP-2 is one of the three chemokine-like proteins expressed by the human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus, KSHV) and the other is ViMIP-1 and ViMIP-3. It shares 41 % and 48 % with human MIP-1α and ViMIP-1, respectively. ViMIP-2 has been shown to have antagonist activity towards a wide range of chemokine receptors and has functions of blocking infection by several different human immunodeficiency virus type 1 (HIV-1) strains. It may form part of the response to host defenses contributing to virus-induced neoplasia and may have relevance to KSHV and HIV-I interactions. Additionally, ViMIP-2 has been shown to activate and chemoattract human eosinphil